158 related articles for article (PubMed ID: 28260018)
1. Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
Tamaki R; Kanai-Mori A; Morishige Y; Koike A; Yanagihara K; Amano F
Oncol Rep; 2017 Apr; 37(4):2366-2374. PubMed ID: 28260018
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer.
Matsuzaki T; Yashiro M; Kaizaki R; Yasuda K; Doi Y; Sawada T; Ohira M; Hirakawa K
Cancer Sci; 2009 Dec; 100(12):2402-10. PubMed ID: 19764996
[TBL] [Abstract][Full Text] [Related]
3. [A case of nonresectable scirrhous type gastric cancer successfully treated by low-dose cisplatin (CDDP), 5-fluorouracil (5-FU) and pirarubicin (THP)].
Gochi A; Murashima N; Gotoh K; Matsuno T; Matsuoka J; Tanaka N; Orita K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):905-8. PubMed ID: 10897219
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction.
Nakajima K; Okita Y; Matsuda S
Oncol Rep; 2004 Jul; 12(1):85-90. PubMed ID: 15201964
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers.
Abe S; Kubota T; Matsuzaki SW; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M
Anticancer Res; 1999; 19(5C):4581-6. PubMed ID: 10650814
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].
Zhang J; Ji J; Ji YB; Yuan F; Liu BY; Zhu ZG; Lin YZ
Ai Zheng; 2005 Apr; 24(4):432-7. PubMed ID: 15820065
[TBL] [Abstract][Full Text] [Related]
7. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Inoue Y; Tanaka K; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M
Int J Oncol; 2006 Feb; 28(2):479-86. PubMed ID: 16391804
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of multidisciplinary therapy combining neoadjuvant chemotherapy with S-1 plus cisplatin and postoperative sequential chemotherapy in patients with scirrhous gastric cancer.
Oshima T; Kunisaki C; Sato T; Yamada R; Fujii S; Rino Y; Masuda M; Imada T
Hepatogastroenterology; 2012; 59(117):1638-42. PubMed ID: 22115800
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of scirrhous gastric cancer].
Wakui A
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2398-406. PubMed ID: 7944483
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.
Yashiro M; Shinto O; Nakamura K; Tendo M; Matsuoka T; Matsuzaki T; Kaizaki R; Miwa A; Hirakawa K
Int J Cancer; 2010 Feb; 126(4):1004-16. PubMed ID: 19621385
[TBL] [Abstract][Full Text] [Related]
11. [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
Shimoyama S; Imamura K; Katayama A; Hiki N; Shimizu N; Yamaguchi H; Mafune K; Motoi T; Oohashi K; Kaminishi M
Gan To Kagaku Ryoho; 2004 Jun; 31(6):929-32. PubMed ID: 15222115
[TBL] [Abstract][Full Text] [Related]
12. [The role of thymidylate synthetase in sequential dose of MTX and 5-FU in the advanced scirrhous type gastric cancer].
Akazawa S; Yoshida K
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1273-8. PubMed ID: 2837988
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Sasaki T; Koizumi W; Higuchi K; Ishido K; Ae T; Nakatani K; Katada C; Tanabe S; Saigenji K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):988-92. PubMed ID: 17637532
[TBL] [Abstract][Full Text] [Related]
14. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells.
Tendo M; Yashiro M; Nakazawa K; Yamada N; Hirakawa K
Cancer Sci; 2005 Jul; 96(7):451-5. PubMed ID: 16053517
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
[TBL] [Abstract][Full Text] [Related]
17. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells.
Gao K; Liang Q; Zhao ZH; Li YF; Wang SF
World J Gastroenterol; 2016 Mar; 22(10):2971-80. PubMed ID: 26973393
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
20. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.
Shang C; Guo Y; Zhang J; Huang B
Cancer Chemother Pharmacol; 2016 May; 77(5):1061-7. PubMed ID: 27056384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
